Viz.ai gets FDA De Novo approval for AI-enabled heart disease detection

The U.S. Food and Drug Administration’s approval of Viz.ai’s hypertrophic cardiomyopathy establishes a new category for cardiovascular machine learning-based notification software.

WHY IT MATTERS

Viz.ai, a disease detection and intelligent care coordination company, said in its announcement Tuesday that with ML scanning images from across a health system, more patients with suspected HCM can be identified and diagnosed earlier.

“Hypertrophic…